About Goldline Pharmaceutical IPO
Goldline Pharmaceutical Ltd. sells their branded pharmaceutical goods and operates in the marketing and distribution sectors. The company offers several products along different therapeutic segments and caters to doctors, specialists, surgeons, pediatricians, cardiologists as well as critical care consultants.
The company uses an asset-light business model. They partner with third-party manufacturers for the product's manufacturing while concentrating on market analysis, product branding, marketing, and distribution. The company sells its products using a network of distributors, retailers, wholesalers, hospitals, and other health service providers.
Product Portfolio
Goldline Pharma -
-
42 products across Orthopedics, ENT, Gastroenterology, Neurology, Urology, and General Medicine
Goldline Cardinal -
-
54 products catering for Diabetologists, Cardiologists, Endocrinologists and other Physicians
Goldline Aayushman -
-
18 products for Pediatrics, Neonatology and other Child Healthcare
Goldline InLife -
-
22 products for the critical care, intensive care, and specialty surgical services
Goldline Wellness -
-
10 supportive care products used in cancer therapy as well as wellness care
Operations
Currently the company works with 15 manufacturers and 7 distributors. Goldline Pharmaceuticals’ products are sold across the territories of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Goldline Pharmaceutical IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 9,84,000 crores |
| Non-Institutional Investors (NIIs) | 15% | 2,95,200 crores |
| Retail Individual Investors (RIIs) | 35% | 6,88,800 crores |
Goldline Pharmaceutical IPO Financial Highlights
No Data Found
Goldline Pharmaceutical IPO Strengths & Weaknesses
Management comprised of experienced promoters
Asset-light and scalable business model
Wide range of diverse pharmaceutical products
Strong linkages to suppliers and vendors
Distribution and marketing structures already in place
Goldline Pharmaceutical IPO Important Dates & Issue Details
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| 15 May '26 | -- | 18 May '26 |
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 19,68,000 shares (aggregating up to ₹2,58,000 crores) |
| Fresh Issue | 2,56,200 shares (aggregating up to ₹25,62,000 crores) |
| Offer for Sale | 0 shares of ₹10 (aggregating up to To be announced) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 79.7 shares |
| Post-Issue Shareholding | 0 shares |
Goldline Pharmaceutical IPO Lot Size and Investment Details
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Goldline Pharmaceutical ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Goldline Pharmaceutical IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Goldline Pharmaceutical IPO Contact & Registrar Details
Contact Details
Address
103 F-1 Leela Apartment Shilpa Hsg Society Nagpur
Phone Number
Website
Registrar Details
Registrar Name
Bigshare Services Pvt.Ltd.
Phone Number
Optivalue Tek Consulting Ltd IPO Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Cumulative Capital Pvt Ltd |